These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 19616077)

  • 1. Role of the JNK-interacting protein 1/islet brain 1 in cell degeneration in Alzheimer disease and diabetes.
    Beeler N; Riederer BM; Waeber G; Abderrahmani A
    Brain Res Bull; 2009 Oct; 80(4-5):274-81. PubMed ID: 19616077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphorylation-dependent dimerization and subcellular localization of islet-brain 1/c-Jun N-terminal kinase-interacting protein 1.
    Borsello T; Centeno C; Riederer IM; Haefliger JA; Riederer BM
    J Neurosci Res; 2007 Dec; 85(16):3632-41. PubMed ID: 17663463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Islet-brain1/C-Jun N-terminal kinase interacting protein-1 (IB1/JIP-1) promoter variant is associated with Alzheimer's disease.
    Helbecque N; Abderrahamani A; Meylan L; Riederer B; Mooser V; Miklossy J; Delplanque J; Boutin P; Nicod P; Haefliger JA; Cottel D; Amouyel P; Froguel P; Waeber G
    Mol Psychiatry; 2003 Apr; 8(4):413-22, 363. PubMed ID: 12740599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptotic mechanisms in Alzheimer neurofibrillary degeneration: cause or effect?
    Dickson DW
    J Clin Invest; 2004 Jul; 114(1):23-7. PubMed ID: 15232608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of small-molecule inhibitors of the JIP-JNK interaction.
    Chen T; Kablaoui N; Little J; Timofeevski S; Tschantz WR; Chen P; Feng J; Charlton M; Stanton R; Bauer P
    Biochem J; 2009 May; 420(2):283-94. PubMed ID: 19243309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Common pathological processes in Alzheimer disease and type 2 diabetes: a review.
    Li L; Hölscher C
    Brain Res Rev; 2007 Dec; 56(2):384-402. PubMed ID: 17920690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting cell death in dementia.
    Francis P
    Alzheimer Dis Assoc Disord; 2006; 20(2 Suppl 1):S3-7. PubMed ID: 16772754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of JNK-interacting protein JIP-1 and insulin-like growth factor II in Wilms tumour cell lines and primary Wilms tumours.
    Engström W; Granerus M
    Anticancer Res; 2009 Jul; 29(7):2467-72. PubMed ID: 19596915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes.
    Miklossy J; Qing H; Radenovic A; Kis A; Vileno B; Làszló F; Miller L; Martins RN; Waeber G; Mooser V; Bosman F; Khalili K; Darbinian N; McGeer PL
    Neurobiol Aging; 2010 Sep; 31(9):1503-15. PubMed ID: 18950899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synaptic degeneration in Alzheimer's disease.
    Arendt T
    Acta Neuropathol; 2009 Jul; 118(1):167-79. PubMed ID: 19390859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pancreas-brain axis: insight into disrupted mechanisms associating type 2 diabetes and Alzheimer's disease.
    Desai GS; Zheng C; Geetha T; Mathews ST; White BD; Huggins KW; Zizza CA; Broderick TL; Babu JR
    J Alzheimers Dis; 2014; 42(2):347-56. PubMed ID: 24858405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's disease and diabetes: an integrative view of the role of mitochondria, oxidative stress, and insulin.
    Moreira PI
    J Alzheimers Dis; 2012; 30 Suppl 2():S199-215. PubMed ID: 22269163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin resistance, type 2 diabetes, and AD: cerebrovascular disease or neurodegeneration?
    Luchsinger JA
    Neurology; 2010 Aug; 75(9):758-9. PubMed ID: 20739648
    [No Abstract]   [Full Text] [Related]  

  • 15. Common features between diabetes mellitus and Alzheimer's disease.
    Götz J; Ittner LM; Lim YA
    Cell Mol Life Sci; 2009 Apr; 66(8):1321-5. PubMed ID: 19266159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Common pathological processes and transcriptional pathways in Alzheimer's disease and type 2 diabetes.
    Jones A; Kulozik P; Ostertag A; Herzig S
    J Alzheimers Dis; 2009; 16(4):787-808. PubMed ID: 19387113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic links between diabetes and Alzheimer's disease.
    Maher PA; Schubert DR
    Expert Rev Neurother; 2009 May; 9(5):617-30. PubMed ID: 19402773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thyrotropin-releasing hormone-stimulated thyrotropin expression involves islet-brain-1/c-Jun N-terminal kinase interacting protein-1.
    Abe H; Murao K; Imachi H; Cao WM; Yu X; Yoshida K; Wong NC; Shupnik MA; Haefliger JA; Waeber G; Ishida T
    Endocrinology; 2004 Dec; 145(12):5623-8. PubMed ID: 15345675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders.
    Kayed R; Jackson GR
    Curr Opin Immunol; 2009 Jun; 21(3):359-63. PubMed ID: 19482462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic interaction between tau and the apolipoprotein E receptor LRP1 Increases Alzheimer's disease risk.
    Vázquez-Higuera JL; Mateo I; Sánchez-Juan P; Rodríguez-Rodríguez E; Pozueta A; Infante J; Berciano J; Combarros O
    Dement Geriatr Cogn Disord; 2009; 28(2):116-20. PubMed ID: 19684401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.